Th1 down-regulation at the single-lymphocyte level in HCV-related liver cirrhosis and the effect of TGF-β on Th1 response: Possible implications for the development of hepatoma

Hepatology Research

Volumn 24, Issue 3, 2002, Pages 282-289

  Sakaguchi, Eiki ^a   Kayano, Kozo ^a   Segawa, Makoto ^a   Okamoto, Mariko ^a   Sakaida, Isao ^a   Okita, Kiwamu ^a  

^a YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

HCV related liver cirrhosis; Hepatoma; TGF beta; Th1

Indexed keywords

CD3 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA1; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOGENESIS; CELL COUNT; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HEPATITIS C VIRUS; HUMAN; INCUBATION TIME; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LYMPHOCYTE; MONONUCLEAR CELL; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TH1 CELL; VOLUNTEER;

EID: 0036845137     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6346(02)00090-6     Document Type: Article

References (36)

1. Mosmann TR, Coffman RL. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145-73.
2. O'Garra A. Cytokines induce the development of functionally heterogenous T helper cell subsets. Immunity 1998;8:275-83.
3. Roitt I, editor. Essential immunology, 9th ed.. Malden, MA: Blackwell Science, 1997.
4. Kuby J, Cameron J, Todd C, Mitchell J. Immunology, 4th ed.. New York: Freeman and Company, 2000.
5. Kobayashi M, Kobayashi H, Polland RB, et al. A pathogenic role of Th2 cells and their cytokine products on the pulmonary metastasis of murine B16 melanoma. J Immunol 1998;160:5869-73.
6. Zitvogel L, Mayordomo JI, Tjandrawan T, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996;183:87-97.
7. Tsung K, Meko JB, Peplinski GR, et al. IL-12 induces T helper 1-directed antitumor response. J Immunol 1997;158:3359-65.
8. Weiner GJ, Liu HM, Wooldridge JE, et al. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci USA 1997;94:10833-7.
9. Hu H-M, Urba WJ, Fox BA. Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from Type 2 to a type 1 cytokine profile. J Immunol 1998;161:3033.
10. Castilla A, Prieto J, Fausto N. Transforming growth factors β 1 and α in chronic liver disease. Effects of interferon alpha therapy. New Engl J Med 1993;328:1592-8.
11. Tada T, Ohzeki S, Utsumi K, et al. Transforming growth factor-β-induced inhibition of T cell function. J Immunol 1991;146:1077-82.
12. Yamamoto N, Zou J-P, Li X-F, et al. Regulatory mechanism for production of IFN-γ and TNF by anti-tumor T cells or macrophages in the tumor-bearing state. J Immunol 1995;154:2281-90.
13. 2 on the Th1 cell development of naive CD4+ T cells isolated from different mouse strains. J Immunol 1995;155:3788-93.
14. 2 immunotherapy for hepatocellular carcinoma: treatment in a rat tumor model. Ann Surg Oncol 2001;8:32-7.
15. Openshaw P, Murphy EE, Hsken NA, et al. Heterogeneity of intracellular cytokine synthesis at the single-cell level in polarized T helper 1 and T helper 2 populations. J Exp Med 1995;182:1357-67.
16. Jakow SB, Mead JE, Danielpour D, et al. Transforming growth factor-betaisoforms in rat liver regeneration: messenger RNA expression and activation of latent TGF-β. Cell Regul 1991;2:535-48.
17. Russel WE, Coffey RJ, Ouellete AJ, et al. Type beta transforming growth factor reversibly inhibits the early proliferative response to partial hepatectomy in the rat. Proc Natl Acad Sci USA 1988;85:5126-30.
18. Massague J. The transforming growth factor-β family. Annu Rev Cell Biol 1990;6:597-641.
19. Sporn MB, Roberts AB. Transforming growth factor-β: recent progress and new challenges. J Cell Biol 1992;119:1017-21.
20. Friedman SL. Cytokines and fibrogenesis. Semin Liver Dis 1999;19:129-40.
21. Knittel T, Janneck T, Muller L, et al. Transforming growth factor β (1) regulated gene expression of ito cells. Hepatology 1996;24:352-60.
22. Logan A, Green J, Hunter A, et al. Inhibition of glial scarring in the injured rat brain by a recombinant human monoclonal antibody to transforming growth factor-β2. Eur J Neurosci 1999;11:2367-74.
23. Brahmatewari J, Serafini A, Serralta V, et al. The effects of topical transforming growth factor-β2 and anti-transforming growth factor β 2, 3 on scarring in pigs. J Cutan Med Surg 2000;4:126-31.
24. Ledbetter S, Kurtzberg L, Doyle S, Pratt BM. Renal fibrosis in mice treated with human recombinant transforming growth factor-β2. Kidney Int 2000;58:2367-76.
25. Baer HU, Friess H, Abou-Shady M, et al. Transforming growth factor betas and their receptors in human liver cirrhosis. Eur J Gastroenterol Hepatol 1998;10:1031-9.
26. Kinnman N, Andersson U, Hulterantz R, et al. In situ expression of transforming growth factor-β 1-3, latent transforming growth factor-β binding protein and tumor necrosis factor-α in liver tissue from patients with chronic hepatitis C. Scand J Gastroenterol 2000;35:1294-300.
27. Doherty DG, Norris S, McEntee G, et al. The human liver contains multiple populations of NK cells, T cells, and CD3 + CD56 + natural T cells with distinct cytotoxic activities and Th1, Th2 And Th0 cytokine secretion patterns. J Immunol 1999;63:2314-21.
28. Hata K, Van Thiel DH, Herberman RB, Whiteside TL. Phenotypic and functional characteristics of lymphocytes isolated from liver biopsy specimens from patients with active liver disease. Hepatology 1992;15:816-23.
29. Norris S, Collins C, Doherty DG, Smith F, et al. Resident human hepatic lymphocytes are phenotypically different from circulating lymphocytes. J Hepatol 1998;28:84-90.
30. Sobue S, Nomura T, Ishikawa T, Kakumu S, et al. Th1/Th2 cytokine profiles and their relationship to clinical features in patients with chronic hepatitis C virus infection. J Gastroenterol 2001;36:544-51.
31. Hellstrom I, Ledbetter JA, Scholler N, et al. CD3-mediated activation of tumor-reactive lymphocytes from patients with advanced cancer. Proc Natl Acad Sci USA 2000;98:6783-8.
32. 1 production restores immunogenicity in prostate cancer cells. Br J Cancer 2000;83:519-25.
33. Hsieh CL, Chen DS, Hwang LH. Tumor-induced immunosuppression: a barrier to immunotherapy of large tumors by cytokine-secreting tumor vaccine. Hum Gene Ther 2000;20:681-92.
34. Derynck R, Goedel DV, Ullrich A, et al. Synthesis of messenger RNAs for transforming growth factors α and β and the epidermal growth factor receptor by human cancers. Cancer Res 1987;47:707-12.
35. Kiss A, Wang N, Thorgeirsson SS, et al. Analysis of transforming growth factor (TGF)-α/epidermal growth factor receptor, hepatocyte growth factor/c-met, TGF-β receptor typeII, and p53 expression in human hepatocellular carcinoma. Clin Cancer Res 1997;3:1059-66.
36. Large MK, Kittlesen DJ, Hahn YS. Suppression of host immune response by the core protein of Hepatitis C virus: possible implications for Hepatitis C virus persistence. J Immunol 1999;162:931-8.